Corcept Under Fire as FDA Rejection Reveals Allegedly Ignored Warnings

REDWOOD CITY, CA – January 30, 2026 – Corcept Therapeutics is embroiled in a crisis of investor confidence and facing legal scrutiny following the stunning rejection of its key drug candidate, relacorilant. The company’s stock has been decimated, losing over half its value, after revelations that the U.S. Food and Drug Administration (FDA) had allegedly warned the company “on several occasions” not to submit its New Drug Application (NDA)—a stark contradiction to the company’s initial claims of being “surprised and disappointed” by the decision. The fallout has triggered an investigation by the national law firm Berman Tabacco into potential securities law violations, raising critical questions about corporate transparency and governance at the pharmaceutical firm.

A Tale of Two Narratives

The controversy began on New Year's Eve 2025, when Corcept announced it had received a Complete Response Letter (CRL) from the FDA, effectively rejecting its application for relacorilant as a treatment for hypertension secondary to hypercortisolism. The market’s reaction was swift and brutal. Corcept’s stock plunged $35.40 in a single day, a staggering 50.42% drop, to close at $34.80 per share. In its press release, the company conveyed shock at the regulatory setback, a sentiment that investors initially took at face value.

However, that narrative crumbled a month later. On January 30, 2026, a Reuters report, citing a corrected version of the FDA's CRL, painted a dramatically different picture. According to the report, the FDA had explicitly cautioned Corcept during pre-submission meetings to “expect significant review issues” and advised against submitting the NDA in its current form. This revelation sent a second shockwave through the market, causing Corcept's shares to fall another 16%, wiping out approximately $3.2 billion in market capitalization since the end of December. The discrepancy between the company's public posture and the FDA's documented warnings is now the central focus of investigations by investor rights law firms.

Leading up to the rejection, Corcept had projected an aura of supreme confidence. Management had consistently touted relacorilant’s prospects, assuring investors that the application was progressing smoothly toward an approval by the end of 2025. The company went as far as projecting an expansion of its hypercortisolism business from $3 billion to $5 billion in annual revenue within five years, a forecast heavily dependent on relacorilant's success. These optimistic statements now stand in sharp contrast to the FDA’s alleged repeated cautions.

Unpacking the FDA's Scientific Concerns

The FDA's rejection was not merely procedural; it was rooted in deep-seated concerns about the drug's clinical data. The agency concluded it “could not arrive at a favorable benefit-risk assessment for relacorilant” without additional evidence of its effectiveness. While Corcept had highlighted its pivotal Phase 3 GRACE trial as having met its primary endpoint, the FDA pointed to a critical flaw: a high patient dropout rate. Only 45% of patients who started the trial advanced to the randomized phase, leading the agency to conclude that the positive result “likely overestimates the treatment effect.”

Further complicating matters was the failure of a second Phase 3 study, the GRADIENT trial. This study did not meet its primary endpoint of improving systolic blood pressure. Although Corcept presented a post-hoc analysis suggesting “clinically meaningful improvements,” the FDA dismissed these findings as unreliable due to the small number of subjects and significant missing data. The agency’s own analysis found “no nominal statistical significance” for the treatment effect, undermining Corcept's claim that GRADIENT provided the necessary confirmatory evidence for approval.

Beyond efficacy, the corrected CRL also reportedly highlighted “serious liver safety concerns.” This directly contradicts Corcept’s previous public statements asserting that relacorilant was “well tolerated” in both of its major trials, with no significant safety issues observed. The combination of questionable efficacy data and emerging safety signals provided the FDA with a firm basis for its rejection, leaving Corcept with the daunting task of conducting further trials to salvage the drug for this indication.

Financial Fallout and Legal Peril

The financial consequences for Corcept and its investors have been severe. The stock's collapse has not only erased billions in shareholder value but has also forced a major reassessment of the company's future. H.C. Wainwright, an investment bank, slashed its price target for the company and projected a three-year delay for a potential relacorilant launch, pushing the timeline to 2029. Meanwhile, Zacks Investment Research has issued a “Strong Sell” rating on the stock.

The setback is particularly painful as relacorilant was intended to be the successor to Corcept's only marketed product, Korlym, which is also used to treat hypercortisolism and generated over half a billion dollars in the first nine months of 2025. The failure to secure approval for the new drug leaves the company heavily dependent on a single revenue stream and vulnerable in a competitive market projected to reach nearly $1 billion by 2035.

This situation has also placed Corcept in significant legal jeopardy. The investigation by Berman Tabacco is likely the precursor to a securities class-action lawsuit alleging that the company misled investors by omitting material information about its communications with the FDA. This scenario has precedent; the Securities and Exchange Commission (SEC) has previously fined executives from other pharmaceutical companies, such as Spero Therapeutics, for misrepresenting FDA feedback. For Corcept, the road ahead involves not only a challenging path back to the FDA but also a potentially costly legal battle that will scrutinize its every public statement. All eyes are now on the company's next steps, including the fate of a separate NDA for relacorilant as a treatment for ovarian cancer, for which the FDA has set a decision date of July 11, 2026.